PD. Dr.rer.nat. Obul R Bandapalli is a functional genomics researcher with special focus on transnational research. He is currently working at DKFZ, Heidelberg, Germany. He finished his habilitation in Molecular Medicine from the Molecular Medicine Partnership Unit of EMBL-University of Heidelberg and continues to teach at the University of Heidelberg. He has PhD in Molecular Biology from Humboldt University. Before moving to Germany he has worked at the Central Food Technological Research Institute Mysore, Dabur Research Foundation and Jawaharlal Nehru University, New Delhi, India. He obtained his Master´s in Biotechnology from Guru Ghasidas University and Bachelor’s in Sericulture from Sri Venkateswara University. Apart from research, he enjoys watching birds and nature trails.
Professor of Veterinary Pathology at University of Guelph & President-Elect of the American College of Veterinary Pathologists
Interested in a better understanding of animal diseases and their counterparts in human disease Also interested in developing new tools to investigate animal diseases
Obtained her PhD degree in the University of Paris VII in 1993, and trained as a post-doc in Prof. John Dick’s group in Toronto. In 1998, she became Group Leader at the Coriell Institute for Medical Research and Assistant Professor, University of Medicine and Dentistry of New Jersey. In 2001, she joined the London Research Institute. Since 2002, she is also Professor, University College of London and Senior Lecturer at the Institute of Child Health.
Graduated in Medicine in 1988 at the University of Padua. Pediatrician in 1992. I have been actively involved in pediatric hematology and oncology, especially in chemotherapy for leukemia and lymphoma, supportive care, and early and late effects of treatment, and hematopoietic stem cell transplantation (HSCT).
Appointed in 2009 Director of the Pediatric Hematology and Oncology Unit at the Department of Pediatrics in Verona. Member of the scientific committees of several working groups including Pediatrics (for MASCC), Supportive Care (for SIOP), Aplastic Anemia, Infection (for EBMT), hematopoietic stem cell transplant, Infection, Supportive care (for AIEOP). Appointed in 2005 and 2015 Chairman of the Supportive Care Group and Infection of AIEOP (Italian Association of Pediatric Hematology Oncology), respectively. Appointed in 2010, Chairman of Infectious Diseases Working Party of European Society for Blood and Marrow Transplantation.
Author of more than 200 publications in peer-reviewed journals. Medical advisor of the charities Paul O’Gorman Lifeline (UK) and Lifeline Italia, liaising with and advising pediatric hematology and oncology centers in Russia, Ukraine, Georgia and Kyrgyzstan.
Senior Lecturer in Biological Sciences at the University of Huddersfield, since 2015. Previously Junior Research Fellow, College Lecturer In Biochemistry and various postdocs at the University of Oxford (2013-15). Working on DNA replication, genome integrity and transcription factors in human cancers (and also in prokaryotes). Additional interests in phylogenomics and novel protein expression systems.
Principal Investigator of the Transfusion Research Center, Belgian Red Cross Flanders, Belgium. Visiting Professor at Ghent University, Faculty of Medicine.
Roi Gazit, PhD., is Principal Investigator of Hematopoietic Stem Cell (HSC) transcriptome laboratory at the Ben-Gurion University of the Negev, Israel. He is a member of the National Institute for Biotechnology in the Negev (NIBN), and the Center for Regenerative Medicine and Stem Cells at BGU. Roi earned a B.Sc. and M.Sc. in life science and developmental biology from the Hebrew University of Jerusalem. He obtained PhD. in immunology, under supervision of Ofer Mandelboim, studying NK-cell in vivo, including the generation of the first NK specific mouse model and elucidation of novel NK-cell abnormalities in human patients. He conducted postdoctoral studies at the Harvard Medical School, at Derrick J. Rossi laboratory, focusing on the identification and utilization of HSCs’ genes, including reprogramming of committed blood cells into HSCs using defined transcription-factors and generation of a novel HSC-reporter mouse. His laboratory at the Ben-Gurion University is studying HSCs’ transcriptome along normal development, during immune-challenges, and the direct reprogramming of adult blood cells into HSCs.
Assistant Professor of Pediatrics at the Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College of Cornell University.
He leads research in the functional proteomics and genomic plasticity of refractory childhood cancers.
Professor of Molecular and Cellular Glycobiology, Department of Biological Science, College of Science, Sungkyunkwan University, Korea,
Co-positional Professor of Department of Medical Device Management and Research,
Samsung Advanced Institute of Health Science and Technology (SAIHST), Former Chairman, Department of Biochemistry and Molecular Biology, COM, DGU. Former Senior Researcher of KRIBB. University of Tokyo MS, PhD. 324 peer reviewed publications. Intl Advisory Bord and Chairs, Intl Symposium on Glycosyltransferases GlycoT2008 and GlycoT2012, Chair of Molecular Eng-2013 TX, USA. Editor, Journal of Glycobiology; eCAM, Current Pharmaceutical Biotechnology and others.
Dr. Can Küçük currently works at Dokuz Eylül University and İzmir Biomedicine and Genome Center (IBG) in Turkey as a faculty and independent PI with his own research group. He has authored research articles in high profile journals on molecular pathobiology, genetics, or diagnostics of NK and/or T cell malignancies.
Dr. Küçük graduated from the Department of Molecular Biology and Genetics at Middle East Technical University (METU) in 2005. He got his Ph.D degree in Cancer Biology and Oncology from Eppley Institute for Research in Cancer and Allied Diseases at University of Nebraska Medical Center (UNMC) in 2012. He worked as a post-doc in the Department of Pathology at UNMC and then at City of Hope Medical Center.
His group investigates the etiology of lymphoid malignancies using personalized medicine approach. In particular, targeted sequencing, whole transcriptome sequencing, or epigenome sequencing are applied on tumor samples to identify aberrant genes or pathways leading to development of these neoplasms. His group aims to:
1) identify novel recurrent aberrations that can be targeted by rational drugs.
2) develop companion diagnostics methodologies for personalized medicine
3) identify novel biomarkers of diagnosis, prognosis or disease management.
My research group is working to identify genetic mutations that contribute to the development of leukaemia, and studying how these mutations influence a patient’s response to therapy. The cancer landscape is both complex and dynamic and we're using genomic approaches to study how cancer cells evolve in response to treatment.
I obtained my PhD from the Institute of Cancer Research in London spent a further 10 years there as a postdoctoral fellow and Staff Scientist. I am currently a Lecturer in Molecular Biology at the University of Stirling in Scotland. My principal research interest is translational oncology, with a focus on epigenetics.